Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...
Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback